Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (2016 - 2025)

Editas Medicine (EDIT) has disclosed Shares Outstanding for 11 consecutive years, with $93.3 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding rose 12.99% to $93.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $93.3 million through Sep 2025, up 12.99% year-over-year, with the annual reading at $82.7 million for FY2024, 1.18% up from the prior year.
  • Shares Outstanding for Q3 2025 was $93.3 million at Editas Medicine, up from $87.4 million in the prior quarter.
  • The five-year high for Shares Outstanding was $93.3 million in Q3 2025, with the low at $67.5 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $76.6 million, with a median of $81.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 23.12% in 2021, then rose 0.57% in 2023.
  • Over 5 years, Shares Outstanding stood at $68.4 million in 2021, then rose by 0.6% to $68.8 million in 2022, then rose by 18.77% to $81.8 million in 2023, then grew by 1.18% to $82.7 million in 2024, then rose by 12.73% to $93.3 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $93.3 million, $87.4 million, and $83.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.